NDA 217603 · Tarsus
Xdemvy
Lotilaner · Ophthalmic · Ectoparasiticide
NovelCDER novel approval, Jul 25, 2023: To treat Demodex blepharitis
Last checked: Nov 20, 2026Latest source record: Jul 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jul 24, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
3 Phase 3, 1 recruiting
FAERS reports
3,918
320 serious, 39 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 10, 2024.
XDEMVY is indicated for the treatment of Demodex blepharitis. XDEMVY is an ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis. ( 1 )
Mechanism: Lotilaner is a gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor selective for mites. Inhibition of these GABA chloride channels causes a paralytic action in the target organism leading to its death. Lotilaner is not an inhibitor of mammalian GABA mediated chloride channels when tested at up to 30 µM (18 µg/mL) in vitro (approximately 1100 times the RHOD).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- XDEMVY · LOTILANER 0.25% · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lotilaner" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick ExposurePivotal-lookingActive, not recruiting
Tarsus Pharmaceuticals, Inc.Industry
NCT07562087 · 722 participants · Start Mar 9, 2026 · Primary completion Oct 2027
Drug: TP-05 (lotilaner) Low Dose; TP-05 (lotilaner) High Dose and 1 more · For: Lyme Disease
Sites: Pikesville, Maryland; Brookline, Massachusetts; Fall River, Massachusetts · 19 sites in all
- Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisPivotal-lookingCompleted
Tarsus Pharmaceuticals, Inc.Industry
NCT04475432 · 421 participants · Start Sep 9, 2020 · Primary completion May 4, 2021
Drug: TP-03, 0.25%; TP-03 Vehicle · For: Blepharitis
Sites: Phoenix, Arizona; Newport Beach, California; Colorado Springs, Colorado · 15 sites in all
- Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisPivotal-lookingCompleted
Tarsus Pharmaceuticals, Inc.Industry
NCT04784091 · 412 participants · Start Apr 29, 2021 · Primary completion May 9, 2022
Drug: TP-03; TP-03 Vehicle · For: Blepharitis
Sites: Scottsdale, Arizona; Northridge, California; San Ramon, California · 21 sites in all
- Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA StudyPivotal-lookingCompleted
LianBio LLCIndustry
NCT05629390 · 163 participants · Start Oct 23, 2022 · Primary completion Sep 15, 2023
Drug: Lotilaner; Vehicle Control · For: Blepharitis
Sites: Beijing, China; Chongqing, China; Xiamen, China · 21 sites in all
- Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)Pivotal-lookingEnrolling by invitation
Tarsus Pharmaceuticals, Inc.Industry
NCT07443202 · 155 participants (planned) · Start Dec 5, 2025 · Primary completion Dec 31, 2026
Drug: lotilaner; Vehicle · For: Ocular Rosacea
Sites: Houston, Texas; Lynchburg, Virginia
- Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens WearersPivotal-lookingCompleted
Tarsus Pharmaceuticals, Inc.Industry
NCT06182358 · 145 participants · Start Dec 27, 2023 · Primary completion Jan 27, 2025
Drug: Lotilaner ophthalmic solution, 0.25%; Vehicle control · For: Demodex Blepharitis
Sites: Cave Creek, Arizona; Long Beach, California; Colorado Springs, Colorado · 14 sites in all
Medicines for Malaria VentureAcademic, hospital or other
NCT07758985 · 75 participants (planned) · Start Sep 14, 2026 · Primary completion Aug 2027
Drug: Cohort 1 low dose lotilaner with a high-fat meal; Cohort 2 high dose lotilaner in fasted state and 1 more · For: Malaria
Sites: Bamako, Mali
Tarsus Pharmaceuticals, Inc.Industry
NCT05138796 · 67 participants · Start May 6, 2021 · Primary completion Mar 25, 2022
Drug: TP-05 (lotilaner oral capsules); Placebo · For: Healthy
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation491
- off label use417
- ocular hyperaemia322
- product use issue315
- condition aggravated280
- eye pain277
- vision blurred267
- therapy interrupted253
- wrong technique in product usage process252
- eye pruritus214
- drug ineffective199
- product prescribing issue167
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 22 |
| 2024 | 776 |
| 2025 | 1,254 |
| 2026 | 1,863 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xdemvy (Lotilaner)
2024 spending
$114M
Beneficiaries
57,626
61,184 claims
Per beneficiary
$1,983
$186.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $7,089,001 |
| 2024 | $114,252,679 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).
Gaddie IB, Donnenfeld ED, Karpecki P, et al. · Ophthalmology 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in the Treatment of Demodex Blepharitis: A Systematic Review and Meta-Analysis.
Abo Zeid M, Elrosasy A, Abbas AW, et al. · Ocul Immunol Inflamm 2024 · Systematic Review, Meta-Analysis
- Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies.
Talha M, Haris Ali M, Fatima E, et al. · Am J Ophthalmol 2024 · Systematic Review, Meta-Analysis
- Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials.
Muhammad Muneeb Akhtar S, Fareed A, Sohaib Asghar M, et al. · Cont Lens Anterior Eye 2024 · Meta-Analysis, Systematic Review
- Safety evaluation of lotilaner in dogs after oral administration as flavoured chewable tablets (Credelioࡊ).
Kuntz EA, Kammanadiminti S · Parasit Vectors 2017 · Randomized Controlled Trial
- Assessment of the onset of lotilaner (Credelioࡊ) speed of kill of fleas on dogs.
Cavalleri D, Murphy M, Seewald W, et al. · Parasit Vectors 2017 · Randomized Controlled Trial
Sponsor: Tarsus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.